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them is an essential component of CER. The Atrial Fibrillation methods guidance
was developed in a unique process to improve the future quality of evidence with
a balance between internal validity and external generalizability.
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OBJECTIVES: The German legislator introduced early benefit assessments of al-
most all new drug approvals in 2011. Within one year after approval, the pharma-
ceuticalmanufacturer and the Statutory Health Insurance funds negotiate a rebate
based on the early benefit assessment. For each new drug, a common rebate for all
indications is negotiated. Therefore, themanufacturer needs to analyzewhether or
not to seek approval for each potential indication. We aim to analyze the manu-
facturer’s decision. METHODS: We develop a binary decision model to determine
profitability of each indication. Profitability is defined as a positive contribution to
the manufacturer’s global revenue. We apply our model to Ticagrelor as an exam-
ple. Ticagrelor was the first drug that was subject to an early benefit assessment.
The assessment is publicly available and delivers information for four indications.
RESULTS: The approval decision for a specific indication depends on five factors: 1)
Expected benefit as determined by the early benefit assessment; 2) Expected DDDs
in Germany; 3) Willingness for off-label use in the indication in Germany; 4) Ex-
pected DDDs globally; and 5) Impact of the German price on the mean global price.
CONCLUSIONS: The approval decision proves to be complex. Ticagrelor’s early
benefit assessment has shown the important role of the comparator used in the
assessment. The manufacturer named no trials to prove benefit over the adequate
comparators for STEMI (percutaneous coronary intervention) and STEMI (coronary
artery bypass grafting). Willingness for off-label use, however, is high, as currently
observed for Clopidogrel. For such a case, our model shows that it is profitable to
just seek approval for the indication with the greatest additional benefit (unstable
angina/NSTEMI). Based on the best indication, the manufacturer can negotiate a
smaller rebate. Additional revenue is generated if off-label prescriptions are com-
mon in other indications.
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OBJECTIVES: To evaluate the impact of Food and Drug Administration (FDA) safety
warning on the utilization rates of thiazolidinedione oral anti-diabetes medica-
tions using an interrupted time series analysis.METHODS: The analysis used data
from the five percent national sample of Medicare Part D beneficiaries. Beneficia-
ries were included if they were diabetic, continuously enrolled in Part D and had
filled a prescription for a thiazolidinedione medication at any time during the
period of January 2006 through December 2008. Beneficiaries were classified each
month into appropriate-use, at risk, and contraindicated groups based on the pres-
ence of certain comorbid conditions. Data were aggregated to monthly utilization
rates. Analyses examined the effects of the May 2007 FDA safety warnings about
the ongoing review of rosiglitazone’s potential to increase cardiovascular risks on
thiazolidinedione utilization rates for the different appropriateness of use catego-
ries using an interrupted time series consisting of 32 data points (13months before
and 19 months after the safety warning). RESULTS: There was an increasing trend
in the total utilization rates of thiazolidinediones before the safety warning. Sig-
nificant decline in drug utilization rates were observed at the end of the study
period for all patient groups on rosiglitazone (relative difference -74.78%, -79.93%,
and -90.21% in appropriate-use, at risk and contraindicated patient groups, respec-
tively). The intervention did not have significant immediate effects on the post-
intervention utilization rates of pioglitazone. However, after the intervention, a
general decline in utilization of thiazolidinediones, including pioglitazone, was
observed. CONCLUSIONS: The initial safety warning about rosiglitazone’s cardio-
vascular safety was effective in decreasing rosiglitazone’s utilization in the tar-
geted population and thus appeared to achieve the desired safety effects. The
safety warning, however, also had spillover effects by reducing utilization of drugs
in other patient cohorts not targeted by the warning.
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OBJECTIVES: Pharmaceutical expenditure is rapidly growing and accounts for
40-50 percent of total medical care expenditures. In order to contain drug expen-
diture growth effectively, we need to understand what the drivers are. This study
aims to answer the question by decomposing the pharmaceutical expenditure
changes into prices, volume, and product substitution effects.METHODS: By using
quarterly drug sales records from 2006-2011 of a large public hospital in Sichuan
province, we analyze the pharmaceutical expenditure changes for two therapeutic
groups: antibiotics (249 products molecules with 2491 records) and cardiovascu-
lar(130 products molecules with1668 records). After standardizing volume and
price recommended by DDD (WHO), a statistic index factor analysis is employed.
Specifically, Laspeyres price index (LPI) and chained LPI are employed to calculate
the price changes with and without entry and exit of products over time. We also
take a closer look at the substitution pattern, including shift among therapeutic
groups, shift between brand and generic drugs, and shift between old and new
drugs. RESULTS: Our results show that both antibiotics and cardiovascular drug
expenditures increased over 30% in the past 5 years. Interestingly, prices are con-
tinuously dropping and the volumes are slightly increasing for both antibiotics and
cardiovascular drugs. Relatively speaking, substitution effect plays the most im-
portant role in expenditure growth. Specifically, proportions of brand-name drugs,
new drugs, and more therapeutic advanced drugs are increasing over time.
CONCLUSIONS: Our study indicates that the key factor that contributes to the
expenditure growth is product substitution effect. Thus, price control policies may
not be an effective way to control the rapid pharmaceutical expenditure growth.
Instead, more attention should be paid on how to control the substitution shifts,
whichmay be caused by prescriber behavior and consumer demand. Further anal-
ysis should also be on the impact of substitution shift on quality of health care.
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OBJECTIVES: To assess the prevalence and determinants of pharmacotherapy in
patients with myocardial infarction. METHODS: The Medical Expenditure Panel
Survey (MEPS) data from 2004 to 2008 were used to conduct a retrospective cross-
sectional study. Study sample included adults  18 years with myocardial infarc-
tion. Pharmacotherapy was defined as the use of aspirin, beta-blockers, statins or
ACEI/ARB. Descriptive characteristics were used to describe the study sample and
utilization patterns. The predictors of pharmacotherapy use were modeled based
on the Andersen Behavior Model using logistic regression. The year variable and
the Charlson’s comorbidity index score (CCI) was also included in the analyses. A
p-value of 0.05was considered to be statistically significant. RESULTS:According to
theMEPS, 55% of the patients received ACEI/ARBs, 68% received beta-blockers, 64%
received statins and 75% received aspirin. Individuals who had a usual source of
healthcare were twice asmore likely to receive ACEI/ARBs (OR: 2.15; CI: 1.20 – 3.84).
Also, patients who were publicly insured (OR: 0.50; CI: 0.28 – 0.90), those who re-
sided in metropolitan region (OR: 0.69; CI: 0.50 – 0.95) and patients having a CCI
score of 2, 3 or 4 were less likely to receive ACEI/ARBs. Females (OR: 0.63; CI: 0.44 –
0.91), blacks (OR: 0.45; CI: 0.30 – 0.66) and individuals who had a CCI score of 10 (OR:
0.22; CI: 0.08 – 0.58) were less likely to receive beta-blockers. Also, as age increased,
the likelihood of taking beta-blockers (OR: 1.22; CI: 1.11 – 1.34) and aspirin (OR: 1.24;
CI: 1.11 – 1.39) increased. Patients who had a usual source of healthcare were 3
times as likely to receive statins (OR: 3.05; CI: 1.53 – 6.10). CONCLUSIONS: Analyses
of national level data revealed suboptimal utilization of evidence-based pharma-
cotherapy for management of myocardial infarction. Concerted efforts are needed
to optimize pharmacotherapy in patients with myocardial infarction.
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OBJECTIVES: Results from several clinical trials have showed that rhythm-control
drugs, which have serious adverse events, have no survival advantage over rate-
control drugs in patients with atrial fibrillation (AF). The objective of the study was
to determine 1) the trends in utilization for rate-control and rhythm-control drugs
from 2001 to 2009; and 2) if the utilization of rhythm-control drugs decreased over
time. METHODS: The physician’s-office and outpatient data components of the
National Ambulatory Medical Care Survey (NAMCS) from 2001 to 2009 were used.
Visits with AF were identified by ICD-9 diagnosis code, ‘427.31’. From these visits,
visits with mentions of rate-control drugs, beta blockers (e.g. metoprolol, propran-
olol, carvedilol, etc.) and non-dihydropyridine calcium channel blockers (vera-
pamil and diltiazem) and visits with mentions of rhythm-control drugs ( e.g. ami-
odarone, disopyramide, propafenone, etc.) were identified using drug codes
provided by NAMCS. Trends in utilization were calculated as total number of visits
with prescriptions divided by total number of visits with AF for each year.
RESULTS: From 2001 to 2009, visits with AF rose from 6.83 million to 11.56 million.
The prescription rate for rate-control drugs increased from 24.28% to 62.31% from
2001 to 2009. The prescription rate for rhythm-control drugs remained the same,
5.31% in 2001 and 5.14% in 2009. The prescription rate for any pharmacotherapy for
AF increased from 29.32% to 67.44% from 2001 to 2009. CONCLUSIONS: The utili-
zation of rhythm-control drugs remained constantwhile that of rate- control drugs
increased from 2001 to 2009. Previously, the treatment approach for AF was to
achieve normal sinus rhythm with rhythm-control drugs and direct current car-
dioversion, rather than use the rate-control drugs. Following the trials on rate-
control and rhythm-control drugs, the use of rate-control strategy increased.
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